1,496
Participants
Start Date
December 31, 2007
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
Naltrexone SR 32 mg/bupropion SR 360 mg/day
Placebo
Ancillary therapy
Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Comprehensive Weight Control Program, New York
Behavioral Medical Research, Staten Island
Central New York Clinical Research, Manlius
Geisinger Medical Center, Danville
George Washington University, Washington D.C.
Metrolina Medical Research, Charlotte
Mountain View Clinical Research, Greer
Palmetto Medical Research, Mt. Pleasant
Clinical Research Atlanta, Stockbridge
Comprehensive NeuroScience, Inc, Atlanta
Suncoast Clinical Research, Palm Harbor
Clinical Research Associates, Inc., Nashville
Trover Center for Clinical Studies, Madisonville
Patient Priority, Cincinnati
Wells Institute For Health Awareness, Kettering
Northwest Indiana Center for Clinical Research, Valparaiso
Summit Research Network, Inc., Okemos
Twin Cities Clinical Research, Brooklyn Center
Mercy Health Research, St Louis
Radiant Research, Inc., St Louis
HealthStar Research, Hot Springs
The Cooper Institute, Dallas
Center for Human Nutrition University of Colorado Health Sciences Center, Denver
Lovelace Scientific Resources, Phoenix
HOPE Research Institute, Phoenix
Lovelace Scientific Resources, Albuquerque
Clinical Research Center of Nevada, Las Vegas
Pharmacology Research Institute, Newport Beach
Sierra Medical Research, Fresno
The Portland Clinic, Portland
Summit Research Network, Inc., Seattle
Northern California Research, Carmichael
Chase Medical Research, LLC, Waterbury
Nutrition and Weight Mangement Center Boston Medical Center, Boston
Milford Emergency Associates, Inc, Milford
Endocrinology & Diabetes Consultants, Dover
Lead Sponsor
Orexigen Therapeutics, Inc
INDUSTRY